(Q37173199)

18 August 2017

1 reference

title

Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? (English)

1 reference

18 August 2017

3

Mark J Ratain

1 reference

18 August 2017

2

Federico Innocenti

1 reference

18 August 2017

Minoli A Perera

1

1 reference

PubMed ID

18503403

18 August 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

28

1 reference

18 August 2017

6

1 reference

18 August 2017

755-768

1 reference

Genetic Control of Drug Levels in Man: Antipyrine

18 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

SNP databases and pharmacogenetics: great start, but a long way to go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Regulation of UDP glucuronosyltransferase genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

The human UDP-glucuronosyltransferases: structural aspects and drug glucuronidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Structural and functional studies of UDP-glucuronosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Induction of rat UDP-glucuronosyltransferases in liver and duodenum by microsomal enzyme inducers that activate various transcriptional pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Induction of human UDP-glucuronosyltransferase 1A1 by cortisol-GR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Effects of St. John's wort on irinotecan metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Human UDP-glucuronosyltransferases: metabolism, expression, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Pharmacogenetic approach for cancer treatment-tailored medicine in practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Molecular genetic basis of Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Mechanism of indinavir-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer Susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Adding pharmacogenetics information to drug labels: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Consent and privacy in pharmacogenetic testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Pharmacogenetics and ethical considerations: why care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

Informed lay preferences for delivery of racially varied pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.6.755

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.6.755

1 reference

18 August 2017

1 reference

PubMed ID

18503403